Login
$NRXP
$2.13 -$0.02 (0.93%) Pre-market

$NRXP 8-K SEC Filings

Filed On Filing
02 Nov 2026 8-K: Regulation FD Disclosure

Preservative-Free Ketamine is an American-manufactured presentation of ketamine that contains no benzethonium chloride (BZT), a toxic antimicrobial preservative that is not Generally Recognized as Safe (GRAS) by the FDA. Current law requ...

16 Oct 2026 8-K: Other Events

On October 16, 2026, the board of directors (the “Board”) of NRx Pharmaceuticals, Inc. (the “Company”) established December 17, 2026 as the date of the 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) and set October 28, 2...

05 Oct 2026 8-K: Entry into a Material Definitive Agreement

NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression

16 Sep 2026 8-K: Other Events

NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine

14 Sep 2026 8-K: Regulation FD Disclosure

On September 8, 2026, representatives of NRx Pharmaceuticals, Inc. (the “Company”) used the investor presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K in connection with presentations and meetings with investors a...

17 Aug 2026 8-K: Results of Operations and Financial Condition

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET

07 Aug 2026 8-K: Regulation FD Disclosure

As previously disclosed, NRx Pharmaceuticals Inc. (the “Company”) filed an Abbreviated New Drug Application (“ANDA”) for preservative free ketamine in September 2025. The FDA advised the Company on July 30, 2026 of a final determination ...

22 Jul 2026 8-K: Other Events

In April 2026, NRx Pharmaceuticals, Inc. (the “Company”) announced the incorporation of NRx Defense Systems, Inc. (“NRXD”), a Florida-based research and development subsidiary charged with the development of neuroplastic treatments that ...

04 Jun 2026 8-K: Entry into a Material Definitive Agreement; Other Events

NRx Pharmaceutics, Inc., a Delaware corporation (the “Company”) proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters,” which term shall also include any underwriter substituted as hereinafter prov...

02 Jun 2026 8-K: Other Events

WILMINGTON, Del., June 2, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it intends to offer shares of its comm...

24 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

This Amendment No. 1 (this “Amendment”) to the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan, as amended (the “Plan”) was adopted by the Board of Directors (“Board”) of NRx Pharmaceuticals, Inc., a Delaware corporation (the “Comp...

17 Feb 2026 8-K: Other Events

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting.

17 Feb 2026 8-K: Other Events

We have acted as counsel for NRx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with (a) the Company’s filing on the date hereof with the Securities and Exchange Commission (the “Commission”) pursuant to Rul...

02 Feb 2026 8-K: Departure/Election of Directors or Officers; Compensation

On January 27, 2026, the Board of Directors of the Company appointed Joseph M. Casper, age 75, as the Chief Operating Officer of the Company, effective January 27, 2026.

16 Jan 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Regulation FD Disclosure +1 more

WILMINGTON, Del., Jan. 16, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (the “Company”), a clinical-stage biopharmaceutical company, today announced that it will hold its annual meeting of stockholders (the “2025 Ann...

29 Dec 2025 8-K: Regulation FD Disclosure

Re: Debt Cancellation Agreement/ Pay-Off Letter (the “Letter”).

26 Nov 2025 8-K: Changes in Registrant's Certifying Accountant

We were previously the independent registered public accounting firm for NRX Pharmaceuticals, Inc. and under the date of March 14, 2025, we reported on the consolidated financial statements of NRX Pharmaceuticals, Inc. and Subsidiaries, ...

23 Oct 2025 8-K: Regulation FD Disclosure; Other Events

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director

26 Sep 2025 8-K: Other Events

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx’s

12 Sep 2025 8-K: Completion of Acquisition or Disposition of Assets; Regulation FD Disclosure

Dura Medical, together with pending acquisitions of Neurospa TMS and Cohen & Associates, to provide contiguous coverage at more than 8 locations along Florida’s West Coast, with planned coverage throughout the Florida Peninsula.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support